1. In 1999 it was found that a larger group of PKU/HPA patients also responded to treatment with Schircks Laboratories tetrahydrobiopterin.
1999年,发现有大量的苯丙酮尿症病患群体,并由Schircks实验室提供四氢产品治疗。
2. Ecause there have been extensive clinical trials for their product on large groups of patients, the cost of the tablets is expected to be higher than those supplied by Schircks Laboratories.
iomarin and Merck Serono只会销售100毫克的沙丙蝶呤片。因为他们有更高的临床试验成本,而他们的研发和制作成本远远高于Schircks实验室生产的产品。
3. Please note that the active substance in Biomarin/Merck Serono`s tablets Kuvan is the same as that in Schircks Laboratories Tetrahydrobiopterin tablets.
需要提醒您的是,Biomarin/Merck Serono生产的活性物质,名为Kuvan是和Schircks 实验室的四氢生物蝶呤药片是相同的。
4. Doctors, clinics, health authorities and ethic commissions depended on the supply of tetrahydrobiopterin provided on a compassionate use/named patient basis from Schircks Laboratories over the last 28 years.
因为四氢生物蝶呤缺乏症是由于一个非常罕见的疾病,也是无法进行有组织的临床试验。